Subscribe
dmitrii-guzhanin-istockphoto-com-scales--1
Dmitrii_Guzhanin / iStockphoto.com
18 January 2018Europe

Mixed views on Broad’s fate after EPO revokes CRISPR patent

Commentators have offered differing opinions on the impact of yesterday’s decision by the European Patent Office (EPO) to revoke a CRISPR/Cas9 patent owned by the Broad Institute of Harvard and MIT.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Cambridge University signs partnership to address innovation challenges
30 January 2018   The University of Cambridge has partnered with the University of Copenhagen to address challenges in biomedical innovation law.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Biotechnology
Cambridge University signs partnership to address innovation challenges
30 January 2018   The University of Cambridge has partnered with the University of Copenhagen to address challenges in biomedical innovation law.

More on this story

Biotechnology
Cambridge University signs partnership to address innovation challenges
30 January 2018   The University of Cambridge has partnered with the University of Copenhagen to address challenges in biomedical innovation law.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott